126 related articles for article (PubMed ID: 18024860)
21. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
23. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
Burkart CM; Grisel JJ; Hom DB
Laryngoscope; 2008 Sep; 118(9):1539-41. PubMed ID: 18622319
[TBL] [Abstract][Full Text] [Related]
24. Personalized ovarian cancer treatment.
Rodriguez AO
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):1-2. PubMed ID: 22193244
[No Abstract] [Full Text] [Related]
25. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.
Numnum TM; Rocconi RP; Whitworth J; Barnes MN
Gynecol Oncol; 2006 Sep; 102(3):425-8. PubMed ID: 16797681
[TBL] [Abstract][Full Text] [Related]
26. New agents for the treatment of ovarian cancer: the next generation.
Dupont J; Aghajanian C; Sabbatini P; Spriggs DR
Int J Gynecol Cancer; 2005; 15 Suppl 3():252-7. PubMed ID: 16343241
[TBL] [Abstract][Full Text] [Related]
27. [IV. Targeted therapies for epithelial ovarian cancer].
Mabuchi S; Sasano T; Kawano M; Kimura T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):193-8. PubMed ID: 24826387
[No Abstract] [Full Text] [Related]
28. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.
Monk BJ; Choi DC; Pugmire G; Burger RA
Gynecol Oncol; 2005 Mar; 96(3):902-5. PubMed ID: 15721449
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab (Avastin) for metastic breast cancer.
Med Lett Drugs Ther; 2008 Jun; 50(1287):42-3. PubMed ID: 18509265
[No Abstract] [Full Text] [Related]
30. Treatment of a vasoproliferative tumour with intravitreal bevacizumab (Avastin).
Kenawy N; Groenwald C; Damato B
Eye (Lond); 2007 Jun; 21(6):893-4. PubMed ID: 17347676
[No Abstract] [Full Text] [Related]
31. Hormone-refractory prostate cancer responding to bevacizumab.
Iacobelli S
Int J Urol; 2008 Aug; 15(8):754. PubMed ID: 18786200
[No Abstract] [Full Text] [Related]
32. Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.
González Martín A
Clin Transl Oncol; 2009 Sep; 11(9):559-60. PubMed ID: 19775993
[No Abstract] [Full Text] [Related]
33. [Bevacizumab administered along with chemotherapy results in an improvement in the overall survival in women with advanced breast cancer].
Svoboda M
Klin Onkol; 2010; 23(1):49. PubMed ID: 20192075
[No Abstract] [Full Text] [Related]
34. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
35. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
[TBL] [Abstract][Full Text] [Related]
36. [A new opportunity in ovarian cancer treatment].
Sedláková I
Ceska Gynekol; 2012 Oct; 77(5):469-71. PubMed ID: 23116353
[TBL] [Abstract][Full Text] [Related]
37. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer.
Koskas M; Chereau E; Ballester M; Selle F; Rouzier R; Daraï E
Anticancer Res; 2010 Nov; 30(11):4743-7. PubMed ID: 21115934
[TBL] [Abstract][Full Text] [Related]
38. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
39. [Digestive neoplasms and bevacizumab].
Bennouna J
J Chir (Paris); 2008 Jan; 145 Spec No 1():1S16-20. PubMed ID: 18575432
[No Abstract] [Full Text] [Related]
40. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.
Rosen A; Thimon S; Ternant D; Machet MC; Paintaud G; Machet L
Br J Dermatol; 2010 Jul; 163(1):225-7. PubMed ID: 20394623
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
